J. Montgomery Keeps Hold on Genta
Genta's (GNTA ) multiple myeloma trial fails to meet a primary endpoint. J. Montgomery kept a hold rating on the stock.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.